The company is targeting left-sided ulcerative colitis with colon-release tablets. Neither peptide is FDA-approved, and the products are still in development.
Recap by typeshit. Full story at Yahoo Finance.
Tara Wider has spent about five years posting on holistic beauty and women's wellness, building a following of women her age on social media.
Brown says diet and exercise still matter, but argues that shaming people for treating obesity with medication has never made anyone healthier.
A short share on growing GLP-1 use in the US, with no figures or sources attached. Thin on detail beyond the headline itself.
A new survey covered by Chain Store Age tracks how GLP-1 users are shifting their food spending from restaurants toward grocery stores.
Lilly's U.S. president says most new Bridge users are new to incretins, while oral Foundayo brought in $184 million in Q3, short of Citi's expectations.
Researchers at nference found pain was the top reason for use and about a third got it from gray-market vendors, while outside experts say benefits remain unproven.
Loading…